Literature DB >> 24141996

p27 Stands-up-to-cancer: UPS nuclear service stops.

Michael V Fiandalo1, Natasha Kyprianou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24141996      PMCID： PMC3800759          DOI： 10.1210/en.2013-1873

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  15 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

3.  Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Chao Yu; Ying Xu; Lian-Jun Guo; Hai-Yi Zhang; Dawang Zhou; Fang-Zhou Song; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-08-30       Impact factor: 5.157

Review 4.  Proteasome inhibitors in cancer therapy: lessons from the first decade.

Authors:  Robert Z Orlowski; Deborah J Kuhn
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

5.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

6.  Proteasomal regulation of caspase-8 in cancer cell apoptosis.

Authors:  Michael V Fiandalo; Steven R Schwarze; Natasha Kyprianou
Journal:  Apoptosis       Date:  2013-06       Impact factor: 4.677

Review 7.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Authors:  Isabel M Chu; Ludger Hengst; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

8.  Specific small molecule inhibitors of Skp2-mediated p27 degradation.

Authors:  Lily Wu; Arsen V Grigoryan; Yunfeng Li; Bing Hao; Michele Pagano; Timothy J Cardozo
Journal:  Chem Biol       Date:  2012-12-21

9.  Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.

Authors:  Savvas C Pavlides; Kuang-Tzu Huang; Dylan A Reid; Lily Wu; Stephanie V Blank; Khushbakhat Mittal; Lankai Guo; Eli Rothenberg; Bo Rueda; Timothy Cardozo; Leslie I Gold
Journal:  Endocrinology       Date:  2013-09-13       Impact factor: 4.736

10.  Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Authors:  Steffan T Nawrocki; Kevin R Kelly; Peter G Smith; Claudia M Espitia; Anthony Possemato; Sean A Beausoleil; Michael Milhollen; Stephen Blakemore; Michael Thomas; Allison Berger; Jennifer S Carew
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.